In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: Review article
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
There is a need to identify subtype-specific ligands for mGlu receptors to elucidate the potential of these receptors for the treatment of nervous system disorders. To date, most mGlu receptor antagonists are amino acid-like compounds acting as competitive antagonists at the glutamate binding site located in the large extracellular N-terminal domain.
We have characterized novel subtype-selective mGlu5 receptor antagonists which are structurally unrelated to competitive mGlu receptor ligands. Using a series of chimeric receptors and point mutations we demonstrate that these antagonists act as inverse agonists with a novel allosteric binding site in the seven-transmembrane domain. Recent studies in animal models implicate mGlu5 receptors as a potentially important therapeutic target particularly for the treatment of pain and anxiety.
- In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: Review article
Volume 23, Issue 1-3 , pp 207-211
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Keywords: Group I metabotropic glutamate receptors
- Industry Sectors
- Author Affiliations
- A1. Nervous System Research, Novartis, Pharma AG, Basel, Switzerland, CH
- A2. Institute of Pharmacology, Polish Academy of Science, Krakow, Poland, PL